Mutations in EGFR and in KRAS usually occur in the founder clones of LAC (most frequently in non-smokers and smokers, respectively), whereas TP53-mutations frequently appear during advanced stages of tumor development, indicating that they play a role during tumor progression rather than initiation [7,11,12,119]. Here, EGFR is linked to neoplasm.